

Supplemental Table 1

Patient	Diagnosis	Sex	Age	Histology	RPA Class	Primary therapy	PFS (months)	OS	MGMT status	NFKBIA status
021	new	m	78	GBM	V	R, RT/TMZ, 2xTMZ (5/28)	4	12	unmet	+/+
023	new	f	79	GBM	V	R ^A	NA	9	meth	+/+
025	new	m	70	GBM	V	R, RT ^A	NA	NA	meth	+/+
035	new	f	75	GBM	IV	R ^B	1	1	unmet	+/+
046 ^D	new	m	76	GBM	IV	R ^B	1	1	unmet	+/-
066 ^D	new	f	69	GBM	IV	R, RT/TMZ ^C	2	2	unmet	+/+
078 ^D	new	m	52	GBM	IV	R, RT/TMZ, 2xTMZ (5/28)	5	10+	unmet	+/-
081	new	w	86	GBM	IV	R ^A	NA	17	unmet	+/+
091 ^E	new	m	52	GBM	IV	R, RT/TMZ, 4xTMZ (5/28)	7	10	unmet	n.d.
106	new	f	68	GBM	IV	R, RT/TMZ, 1xTMZ (5/28)	5	5+	unmet	+/+
116	new	f	67	GBM	IV	R, RT/TMZ	3	7	unmet	n.d.
118 ^E	new	m	63	GBM	IV	R, RT/TMZ, 4xTMZ (5/28)	7	9	unmet	+/-
132 ^E	new	m	75	GBM	IV	R, RT/TMZ, 4xTMZ (5/28)	7	16	unmet	n.d.
135	new	m	41	GBM	IV	R, RT/TMZ ^C	8	9	unmet	+/-
138	new	w	54	GBM	IV	R, RT/TMZ, 5xTMZ (5/28)	10	14+	unmet	+/-
GNV019	new (secondary)	m	9	GBM	NA	R, RT/TMZ	NA	12	unmet	+/++

^A: Patient denied further treatment; ^B: Postoperative complications; ^C: Discontinuation of therapy due to clinical deterioration

^D: Two pGBM samples were derived from this patient, one from the tumor core (center) and the second from the tumor periphery (see (10)).

^E: Two pGBM samples were derived from this patient, one at the time of primary disease and the second at the time of disease recurrence.

meth: methylated MGMT promoter; NA: not assessable; n.d., not determined; OS: Overall survival ; PFS: Progression-free survival; R: Tumor resection; RT: Standard radiotherapy; RT/TMZ: RT plus continuous daily temozolomide (concomitant); TMZ: Temozolomide (5/28: days 1 to 5 out of a 28-day-cycle); unmet: unmethylated MGMT promoter